Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN versus PRASUGREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN versus PRASUGREL.
Aspirin vs PRASUGREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) via acetylation, reducing prostaglandin and thromboxane A2 synthesis. Also activates lipoxin biosynthesis (inflammation resolution).
Prasugrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 receptor on platelets, blocking ADP binding and preventing platelet aggregation.
325-650 mg PO q4-6h prn; max 4 g/day
60 mg orally once daily as a loading dose, then 10 mg orally once daily maintenance
None Documented
None Documented
30 minutes for aspirin (parent drug); salicylic acid: 2-3 hours after low doses, 15-30 hours after high doses due to saturable metabolism and renal reabsorption. Clinical context: prolonged half-life in overdose, renal impairment, and elderly patients.
Clinical Note
moderatePrasugrel + Tranilast
"Prasugrel may increase the anticoagulant activities of Tranilast."
Clinical Note
moderatePrasugrel + Resveratrol
"Prasugrel may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderatePrasugrel + Nimesulide
"Prasugrel may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderatePrasugrel + Epoprostenol
"Prasugrel may increase the antiplatelet activities of Epoprostenol."
The active metabolite has a terminal elimination half-life of about 7 hours (range 2–15 hours). This corresponds to once-daily dosing. Prasugrel itself is rapidly hydrolyzed and has a half-life of about 2 hours.
Renal excretion of salicylates (75-85% as salicyluric acid, 10% as free salicylic acid, 5-10% as glucuronide conjugates); dose-dependent, with renal clearance decreasing at higher doses due to saturation of metabolic pathways. Biliary/fecal elimination is minimal (<5%).
Approximately 68% of the dose is excreted in urine as inactive metabolites, and 27% in feces. No significant renal excretion of parent drug.
Category C
Category A/B
NSAID / Antiplatelet
Antiplatelet